|
|
Vaccine Detail
|
C. muridarum PmpG-1, PmpE/F-2, and MOMP Proteins Vaccine |
| Vaccine Information |
- Vaccine Name: C. muridarum PmpG-1, PmpE/F-2, and MOMP Proteins Vaccine
- Target Pathogen: Chlamydia muridarum
- Vaccine Ontology ID: VO_0004257
- Type: Subunit vaccine
- Status: Research
- Antigen: Chlamydia proteins PmpG-1, PmpE/F-2, and MOMP (Yu et al., 2010).
- Adjuvant:
- Adjuvant name:
- VO adjuvant ID: VO_0001334
- Description: Abisco-100
- Immunization Route: subcutaneous injection
|
| Host Response |
|
Mouse Response
- Host Strain: C57BL/6 and BALB/c
- Vaccination Protocol: Mice were vaccinated 3 times subcutaneously with PmpG-1 plus PmpE/F-2 plus MOMP plus AbISCO-100 (G+F+M+AbISCO) (Yu et al., 2010).
- Challenge Protocol: Two weeks after the final immunization, the mice in the three animal trials described above were then challenged with live EBs for protection evaluation (Yu et al., 2010).
- Efficacy: The combination of three Chlamydia proteins formulated with AbISCO exhibited significant protection at day 13 compared to the group with adjuvant alone (Yu et al., 2010).
|
| References |
Yu et al., 2010: Yu H, Jiang X, Shen C, Karunakaran KP, Jiang J, Rosin NL, Brunham RC. Chlamydia muridarum T-cell antigens formulated with the adjuvant DDA/TDB induce immunity against infection that correlates with a high frequency of gamma interferon (IFN-gamma)/tumor necrosis factor alpha and IFN-gamma/interleukin-17 double-positive CD4+ T cells. Infection and immunity. 2010; 78(5); 2272-2282. [PubMed: 20231405].
|
|
